Telacebec

DRUG2 trials

Sponsors

Qurient Co., Ltd., Barwon Health

Conditions

Buruli UlcerCOVID-19 Virus Infection

Phase 2

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

TerminatedNCT04847583

Qurient Co., Ltd.COVID-19 Virus Infection

Start: 2021-07-29End: 2022-02-11Updated: 2022-03-02

Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)

RecruitingNCT06481163

Barwon HealthBuruli Ulcer

Start: 2024-07-09End: 2028-01-01Target: 200Updated: 2026-06-30